High Noon Just Recalled Thousands Of 12-Packs Mislabeled As Celsius Energy Drinks
On July 29, 2025, High Noon issued a voluntary recall of two production lots of its Beach Variety 12-ounce 12-packs. But what makes this recall unique is that a packaging supplier mistake also roped in Celsius Energy Drink, owned by Celsius Holdings. It's common for drink producers to share suppliers who actually manufacture and distribute cans to factories. Per High Noon's announcement, the supplier accidentally sent empty cans for Celsius's Astro Vibe Sparkling Blue Razz drink to High Noon, which were then filled with vodka seltzer. Factory workers then mistakenly added these mislabeled cans to Beach Variety 12-packs, risking accidental alcohol consumption for consumers who may not have noticed.
While hard seltzers occupy a murky area of alcohol classification between the FDA, Alcohol and Tobacco Trade and Tax Bureau, and the Federal Alcohol Administration Act, mislabeling of any product is a serious issue, especially when alcohol is involved. While this recall is not quite as serious for the general public as a Class One recall of foodstuffs, recent purchasers of High Noon Beach Variety 12-packs should take steps to ensure their products do not fall under the recall.
Read more: 6 Inexpensive Tequilas To Buy And 6 To Avoid, According To Bartender
How To Identify Recalled High Noon And Celsius Energy Drinks
While most alcohol vendors and grocery stores throw out recalled food, it still may be on the consumer to determine if they have a mislabeled product. Though the recall only affects Florida, Michigan, New York, Ohio, Oklahoma, South Carolina, Virginia, and Wisconsin, anyone who purchased a High Noon Beach Variety Pack recently or may consume a Celsius Astro Vibe Sparkling Blue Razz energy drink should carefully evaluate the packaging. This is especially true for anyone under the legal drinking age, may be pregnant, or who abstains from alcohol.
Universal Product Codes (UPC) are retail codes used to track sales of a specific inventory item, but they also help in situations like this. In its announcement, High Noon said the UPC for affected High Noon packages is 085000040065 and the UPC for affected Celsius packages is 8 89392 00134 1. Lot Codes denote specific batches that use the same materials and are great for helping companies determine which products may be affected by recalls. See High Noon's announcement on the FDA website for the lot codes.
If you can't determine if your product is affected by the codes, the unique situation of this recall created an obvious physical indicator. While normal Sparkling Blue Razz flavored drinks have a black lid, affected batches have the silver lid found on High Noon cans. To avoid drinking a mislabeled beverage, avoid any can of this flavor that does not have the correct color of lid.
Want more food knowledge? Sign up to our free newsletter where we're helping thousands of foodies, like you, become culinary masters, one email at a time.
Read the original article on Food Republic.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Astria Therapeutics Announces Positive Initial Results from Long-Term Navenibart Trial in HAE Patients
Astria Therapeutics Inc. (NASDAQ:ATXS) is one of the stocks under $10 to buy now. Earlier on June 13, Astria Therapeutics announced positive initial results from the ALPHA-SOLAR long-term open-label trial of navenibart (STAR-0215) in hereditary angioedema/HAE patients. These findings were presented at the European Academy of Allergy and Clinical Immunology/EAACI Annual Congress. The trial showed an overall reduction in the monthly HAE attack rate, with a 92% mean and 97% median reduction. These results support the potential for every three-month and every six-month dosing regimens for navenibart, as well as its favorable safety and tolerability profile. These initial results from ALPHA-SOLAR are consistent with the 'best-in-class' profile observed in the earlier ALPHA-STAR Phase 1b/2 trial. A closeup of pills in a pharmacy, representing the high quality medications of the company. The ALPHA-SOLAR trial is a long-term, open-label study designed to assess the safety and efficacy of navenibart in adults with HAE Type 1 or 2. All 16 target enrollment participants from the Phase 1b/2 ALPHA-STAR trial opted to enroll in ALPHA-SOLAR. Patients from ALPHA-STAR Cohorts 1 and 2 joined Arm A, while Cohort 3 patients joined Arm B. Astria Therapeutics Inc. (NASDAQ:ATXS) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics for allergic and immunological diseases in the US. While we acknowledge the potential of ATXS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Se produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información
Yahoo
6 hours ago
- Yahoo
Caffeine craze warning after pouches gain in popularity with teens
While the use of caffeine pouches among teenagers remains relatively rare, experts and educators are concerned that may be about to change. Marketing aimed at teenagers of such products is spreading on social media. A school resource officer for the Boise County Sheriff's Office in Idaho, David Gomez, began noticing the use of caffeine pouches last spring, according to NBC News. The pouches can contain more than 200 milligrams of caffeine, and students have been using them along with nicotine pouches such as Zyn. Gomez noted that students would use the pouches as a disguise for nicotine pouches or they'll use both. 'They'll use the Zyn pouches that they put in their lip, and then they'll take a caffeine pouch,' said Gomez. 'They don't care what it is they're putting in their lip.' Richard Mumby is a marketing executive who was part of the launch of the e-cigarette Juul, which has been accused of initiating a wave of teen vaping. He's now back with a caffeine pouch startup known as Wip. A growing market is now trying to sell Americans on pouches as an alternative to caffeinated beverages. Mumby told NBC News that caffeine is part of 'the fabric of many Americans' everyday lives.' But he said there's room to improve. Wip and other companies are marketing caffeine pouches as a portable and affordable alternative to caffeinated drinks. It's a mix between nicotine pouches and energy drinks, placed between the lip and the gums to deliver the caffeine. Pouches, most of which do not contain nicotine, tend to last between 20 minutes and an hour, but their effect can go on for longer. Wip's flavors include mint, strawberry kiwi, and sour cherry, and each comes with 100 or 200 milligrams of caffeine, which is the same as about two cups of coffee. According to the U.S. Food and Drug Administration, that's half the amount of caffeine an adult can safely consume in an entire day. 'We take responsible caffeine consumption and responsible marketing of our product seriously,' a spokesperson for Wip told NBC News. 'While there are no legal age restrictions on caffeine products, we have adopted marketing guidelines that exceed the age-related standards set by the American Beverage Association for most common energy drinks. Wip is not intended for use by anyone under the age of 18, and our guidelines ensure the product is marketed responsibly.' Exercise and nutrition sciences professor at George Washington University's Milken Institute School of Public Health, Rob van Dam, studies caffeine. He shared concerns about the potency of some of the pouches being sold. 'It may be a bit different than coffee,' he told NBC News. 'It may hit faster, and you may overdose, in a way, more quickly.' Another worry is the possible popularity among teens, as nicotine pouches and energy drinks are already widespread. Zyn maker Philip Morris has previously told NBC News that 'Zyn's marketing is directed toward legal age nicotine users who are 21+.' The American Academy of Pediatrics has recommended that teens don't consume more than 100 milligrams of caffeine per day. The chair of the AAP's Committee on Nutrition, Dr. Mark Corkins, told NBC News that it would be better if teens avoided caffeine altogether. 'Caffeine, in general, is an area we are very concerned about,' he said. 'Pouches are just another delivery form.'
CNN
9 hours ago
- CNN
HHS further constrains certain vaccine advisers to the CDC, limiting their input in evidence reviews
In a further jolt to the process of reviewing and recommending vaccines at the US Centers for Disease Control and Prevention, another group of outside advisers to the agency was abruptly sidelined this week. In an email sent late Thursday evening, which was obtained by CNN, members of roughly 30 medical and public health organizations who serve as liaison members of the CDC's Advisory Committee on Immunization Practices, or ACIP, were told they could no longer participate in the committee's crucial workgroups. Liaison members don't vote at ACIP's public meetings on vaccine recommendations, but they can participate by asking questions and commenting on presentations. Behind the scenes, they have also historically done important work undertaking detailed evidence reviews of the safety and effectiveness of vaccines that helps to inform the group's votes. Those reviews happen in subcommittees called workgroups. As of late last year, ACIP had 11 active workgroups. In addition to studying scientific research, workgroups consider issues of public health importance like what age groups might get the most benefit from a vaccine, what an immunization costs and whether it will be accessible to people who should get it. Workgroups also help craft the language of the recommendations that are voted on by the full committee. Votes are typically held during ACIP's three public meetings each year. If ACIP approves a recommendation, it's forwarded to the CDC director for consideration. The director isn't bound by the committee's recommendation but usually follows it. Liaisons include groups like the American Medical Association, the American Academy of Pediatrics and the American Pharmacists Association. Members also represent nurses and public health officials, typically groups that play a significant role in delivering vaccinations. The latest move comes more than a month after US Health and Human Services Secretary Robert F. Kennedy Jr. removed all 17 voting members of ACIP, replacing them days later with eight of his own picks, many of whom have cast doubt on the safety of vaccines and public policy around vaccination. One member later dropped out during the required financial review. The email sent Thursday called the liaison members 'special interest groups' that are 'expected to have a 'bias' based on their constituency and/or population they represent.' 'It is important that the ACIP workgroup activities remain free of any influence from any special interest groups so ACIP workgroups will no longer include Liaison organizations,' the email said. Andrew Nixon, director of communications for HHS, said in a statement Friday that 'Under the old ACIP, outside pressure to align with vaccine orthodoxy limited asking the hard questions. The old ACIP members were plagued by conflicts of interest, influence and bias. We are fulfilling our promise to the American people to never again allow those conflicts to taint vaccine recommendations.' Dr. William Schaffner, an infectious disease expert at Vanderbilt University who has been participating in ACIP for 40 years as both a voting member and a liaison member, said the move to exclude professional organizations from the process of making vaccine recommendations was shortsighted. 'The organizations have a certain ownership in the recommendations because they participate,' Schaffner said. That participation increases buy-in from different stakeholder groups, which helps ACIP recommendations become the accepted standards of medical practice. Without that participation, Schaffner said, there's a risk that groups will make their own vaccine recommendations, which could lead to conflicting and confusing advice. In fact, some outside organizations, including the Vaccine Integrity Project, have already started the process of making independent vaccination recommendations. Shaffner said he also takes issue with the idea that liaison representatives are biased, which he says implies a conflict of interest. 'Every work group member, no matter who they are, is vetted for a conflict of interest,' he said, and that vetting process has only become more stringent over time as society has become more attuned to the problem. 'I have to turn down opportunities because they would interfere with my being on a work group, and that's something I do, or did,' he said. ACIP's charter spells out that some 30 specific groups should hold non-voting seats on the committee. It also allows the HHS secretary to appoint other liaison members as necessary to carry out the functions of the committee. On Friday, eight organizations that are liaisons to the committee said in a joint statement that they were 'deeply disappointed' and 'alarmed' to be barred from reviewing scientific data and informing the development of vaccine recommendations. 'To remove our deep medical expertise from this vital and once transparent process is irresponsible, dangerous to our nation's health, and will further undermine public and clinician trust in vaccines,' said the statement, which was sent by the American Medical Association. New outside experts may be invited to participate in the workgroups as needed based on their expertise, according to an HHS official who spoke on the condition that they not be named because they had not been authorized to share the information, but such inclusion will no longer be based on organizational affiliation. 'Many of these groups don't like us,' the official said. 'They've publicly attacked us.'
